Mobocertinib: Mechanism of action, clinical, and translational science

Abstract Epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations represent ~6%-12% of all EGFR‐mutated non‐small cell lung cancer (NSCLC) cases. First‐, second‐, and third‐generation tyrosine kinase inhibitors (TKIs) have limited clinical activity against EGFR ex20ins mutations...

Full description

Saved in:
Bibliographic Details
Main Authors: Michael J. Hanley (Author), D. Ross Camidge (Author), Robert J. Fram (Author), Neeraj Gupta (Author)
Format: Book
Published: Wiley, 2024-03-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available